Technology
Health
Biotechnology
Veracyte
$21.789876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$21.78
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.07 (-0.32%) Today
-$0.07 (-0.32%) Today
Why Robinhood?
You can buy or sell Veracyte and other stocks, options, ETFs, and crypto commission-free!
About
Veracyte, Inc. engages in the research, development, and commercialization of diagnostic products. Its portfolio includes Afirma, Percepta, and Envisia. Read More It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Employees
270
Headquarters
South San Francisco, California
Founded
2008
Market Cap
892.86M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
362.04K
High Today
$22.00
Low Today
$21.67
Open Price
$21.70
Volume
30.39K
52 Week High
$22.30
52 Week Low
$5.32
Collections
Technology
Health
Biotechnology
Cancer Prevention
2013 IPO
US
North America
Female CEOs
News
Associated Press2h
Veracyte Announces Sponsorship of the Climb to Fight Cancer’s Team Kilimanjaro Expedition
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 19, 2019--Veracyte, Inc. (Nasdaq: VCYT), a leading genomics diagnostics company, today announced its “Summit” level sponsorship of the Climb to Fight Cancer’s Team Kilimanjaro expedition as part of the company’s expanded efforts to combat this disease. Through its sponsorship, the company is supporting “Team Kilimanjaro,” a group of biotechnology executives and investors that will climb Africa’s highest peak in late July 2019 to raise money for Fred Hutchins...
BusinessWireMar 18
Veracyte Announces New Afirma Xpression Atlas Data on Medullary Thyroid Cancer to Be Presented at ENDO 2019
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that new data derived from the Afirma® Xpression Atlas, which help characterize the genomic underpinning of medullary thyroid cancer (MTC), will be presented at ENDO 2019, the Endocrine Society’s annual meeting. The findings on this rare--but aggressive--form of thyroid cancer will be presented in a guided poster presentation during the conference, which is taking place March 23-26 in New Orleans, La. “ The Afirma X...
Yahoo FinanceMar 5
Zacks.com featured highlights include: Radiant, Great Lakes, Clarus, Veracyte and First BanCorp
For Imm ediate Release Chicago, IL – March 5, 2019 - Stocks in this week’s article are Radiant Logistics Inc. RLGT, Great Lakes Dredge & Dock Corp. GLDD, Clarus Corp. CLAR, Veracyte Inc. VCYT and First BanCorp. FBP. 5 Stocks with Recent Price Strength to Maximize Your Gains “In the stock game, winning means reaching a higher price.” However, striking the right chord each time needs a fair amount of luck. No matter how disciplined and systematic investors are, equity market volatility will always manage ...
Price Paid on Robinhood
33% Higher
Right Now
52 Week Low
$5.32
Average Price Paid
$16.37
52 Week High
$22.30
Earnings
-$0.27
-$0.21
-$0.14
-$0.08
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected Apr 30, After Hours